Guyasuta Investment Advisors Has Increased Its Oracle (ORCL) Holding; Epoch Biosciences (EBIO) Sentiment Is 2.25

April 21, 2018 - By Richard Conner

Oracle Corporation (NYSE:ORCL) Logo

Epoch Biosciences Inc (EBIO) investors sentiment increased to 2.25 in Q4 2017. It’s up 1.70, from 0.55 in 2017Q3. The ratio is better, as 9 funds increased and opened new equity positions, while 4 reduced and sold stock positions in Epoch Biosciences Inc. The funds in our database now have: 1.80 million shares, up from 1.21 million shares in 2017Q3. Also, the number of funds holding Epoch Biosciences Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 5 New Position: 4.

Guyasuta Investment Advisors Inc increased Oracle Corp (ORCL) stake by 34.06% reported in 2017Q4 SEC filing. Guyasuta Investment Advisors Inc acquired 99,841 shares as Oracle Corp (ORCL)’s stock declined 4.18%. The Guyasuta Investment Advisors Inc holds 392,968 shares with $18.58 million value, up from 293,127 last quarter. Oracle Corp now has $188.73 billion valuation. The stock decreased 1.26% or $0.59 during the last trading session, reaching $46.23. About 15.68M shares traded. Oracle Corporation (NYSE:ORCL) has risen 1.20% since April 21, 2017 and is uptrending. It has underperformed by 10.35% the S&P500.

Among 42 analysts covering Oracle (NYSE:ORCL), 27 have Buy rating, 0 Sell and 15 Hold. Therefore 64% are positive. Oracle had 115 analyst reports since July 30, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, January 6 by Evercore. The firm has “Buy” rating by KeyBanc Capital Markets given on Monday, July 17. Wells Fargo initiated the shares of ORCL in report on Wednesday, January 11 with “Outperform” rating. On Thursday, June 22 the stock rating was upgraded by Wedbush to “Outperform”. The firm earned “Buy” rating on Friday, December 15 by Canaccord Genuity. JP Morgan upgraded Oracle Corporation (NYSE:ORCL) rating on Wednesday, June 29. JP Morgan has “Neutral” rating and $38 target. The firm has “Buy” rating by Credit Suisse given on Friday, September 15. Cowen & Co maintained Oracle Corporation (NYSE:ORCL) rating on Monday, October 23. Cowen & Co has “Buy” rating and $57.0 target. Wedbush maintained Oracle Corporation (NYSE:ORCL) on Friday, December 16 with “Neutral” rating. UBS maintained Oracle Corporation (NYSE:ORCL) on Thursday, December 17 with “Buy” rating.

Investors sentiment increased to 1.15 in Q4 2017. Its up 0.02, from 1.13 in 2017Q3. It is positive, as 80 investors sold ORCL shares while 488 reduced holdings. 126 funds opened positions while 526 raised stakes. 2.29 billion shares or 1.37% less from 2.32 billion shares in 2017Q3 were reported. St Johns Mgmt Ltd Limited Liability Company holds 17,206 shares. 400 were reported by Cordasco Fincl Ntwk. 5.07 million were accumulated by Apg Asset Mgmt Nv. 53,249 were accumulated by Cetera Advisor Net Limited. Moreover, Bridges Invest Mngmt has 0.04% invested in Oracle Corporation (NYSE:ORCL). Trust Department Mb Comml Bank N A invested in 0.64% or 129,452 shares. Vertex One Asset Mngmt, a British Columbia – Canada-based fund reported 13,000 shares. United Fire Grp has 7,000 shares. Aimz Invest Advisors Ltd Limited Liability Company has 19,826 shares. Great Lakes Advsr Limited Liability Com reported 1.57M shares. Communication Of Vermont has 52,762 shares for 0.23% of their portfolio. Partners Ltd Oh Adv holds 0.64% in Oracle Corporation (NYSE:ORCL) or 18,412 shares. Guardian Capital Lp invested in 0.02% or 33,132 shares. Brandes Prns LP holds 178,736 shares. Stratos Wealth Partners Ltd holds 115,885 shares.

Guyasuta Investment Advisors Inc decreased Mastercard Incorporated (NYSE:MA) stake by 2,097 shares to 226,706 valued at $34.31M in 2017Q4. It also reduced Allergan Plc stake by 11,230 shares and now owns 68,356 shares. Automatic Data Processin (NASDAQ:ADP) was reduced too.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $82.33 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Analysts await Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) to report earnings on May, 3. They expect $-0.13 EPS, up 48.00% or $0.12 from last year’s $-0.25 per share. After $-0.22 actual EPS reported by Eleven Biotherapeutics, Inc. for the previous quarter, Wall Street now forecasts -40.91% EPS growth.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts